Glenn P. Muir
CIK: 0001181190
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Aug 18, 2026CTKB
Cytek Biosciences, Inc.
Exercise(M)Direct3.1K shares- - Jun 10, 2026CTKB
Cytek Biosciences, Inc.
Award(A)DirectDirector Stock Option (right to buy)
29.8K shares- - Jun 10, 2026CTKB
Cytek Biosciences, Inc.
Award(A)DirectRestricted Stock Units
55.6K shares- - May 28, 2026STIM
Neuronetics, Inc.
Award(A)Direct30K shares- - May 14, 2026RGEN
REPLIGEN CORP
Award(A)Direct995 shares- - May 7, 2026RGEN
REPLIGEN CORP
Exercise(M)Direct2.4K shares at avg. $38.76$94K - Dec 16, 2025RGEN
REPLIGEN CORP
Exercise(M)Direct3.4K shares at avg. $26.12$88K - Oct 20, 2025STIM
Neuronetics, Inc.
Award(A)Direct7.6K shares- - May 22, 2025STIM
Neuronetics, Inc.
Award(A)Direct30K shares- - May 15, 2025RGEN
REPLIGEN CORP
Award(A)Direct973 shares- - Feb 7, 2025STIM
Neuronetics, Inc.
Other(J)Direct44.4K shares at avg. $2.25$100K - Nov 19, 2024RGEN
REPLIGEN CORP
Exercise(M)Direct19K shares at avg. $36.29$690K - Sep 18, 2024GTHX
G1 Therapeutics, Inc.
Tender Offer(U)Direct185.4K shares- - Sep 18, 2024GTHX
G1 Therapeutics, Inc.
Disposition(D)Direct20K shares- - Sep 5, 2024STIM
Neuronetics, Inc.
Purchase(P)Direct25K shares at avg. $0.80$20K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 18, 2026 |  CTKB Cytek Biosciences, Inc. | Exercise(M) | 3,086 | - | $0 | Direct |
| Jun 10, 2026 | CTKB Cytek Biosciences, Inc. | Award(A) Director Stock Option (right to buy) | 29,835 | - | - | Direct |
| Jun 10, 2026 | CTKB Cytek Biosciences, Inc. | Award(A) Restricted Stock Units | 55,555 | - | - | Direct |
| May 28, 2026 |  STIM Neuronetics, Inc. | Award(A) | 30,000 | - | $0 | Direct |
| May 14, 2026 |  RGEN REPLIGEN CORP | Award(A) | 995 | - | $0 | Direct |
| May 7, 2026 | RGEN REPLIGEN CORP | Exercise(M) | 2,434 | $38.76 | $94,342 | Direct |
| Dec 16, 2025 | RGEN REPLIGEN CORP | Exercise(M) | 3,366 | $26.12 | $87,920 | Direct |
| Oct 20, 2025 | STIM Neuronetics, Inc. | Award(A) | 7,554 | - | - | Direct |
| May 22, 2025 | STIM Neuronetics, Inc. | Award(A) | 30,000 | - | - | Direct |
| May 15, 2025 | RGEN REPLIGEN CORP | Award(A) | 973 | - | - | Direct |
| Feb 7, 2025 | STIM Neuronetics, Inc. | Other(J) | 44,444 | $2.25 | $99,999 | Direct |
| Nov 19, 2024 | RGEN REPLIGEN CORP | Exercise(M) | 19,000 | $36.29 | $689,510 | Direct |
| Sep 18, 2024 |  GTHX G1 Therapeutics, Inc. | Tender Offer(U) | 185,358 | - | $0 | Direct |
| Sep 18, 2024 | GTHX G1 Therapeutics, Inc. | Disposition(D) | 20,000 | - | $0 | Direct |
| Sep 5, 2024 | STIM Neuronetics, Inc. | Purchase(P) | 25,000 | $0.80 | $20,000 | Direct |
1-15 of 15 transactions
About MUIR GLENN P
MUIR GLENN P (SEC CIK 0001181190) files insider reports with the SEC as Director of Cytek Biosciences, Inc. (CTKB), Director of Neuronetics, Inc. (STIM) and Director of REPLIGEN CORP (RGEN). Signal8 also holds filings tied to 1 other company.
Signal8 holds 14 ownership filings by MUIR GLENN P (1 Form 3, 13 Form 4), filed between Sep 6, 2024 and Aug 20, 2026. Those filings report 15 transactions, from Sep 5, 2024 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on MUIR GLENN P's filings is in FREMONT, CA.
Recent filings by MUIR GLENN P
- Aug 18, 2026: Option exercise of CTKB shares (Form 4, code M).
- Jun 10, 2026: Grants or awards of CTKB derivative securities (2 lines, Form 4, code A).
- May 28, 2026: Grant or award of STIM shares (Form 4, code A).
- May 14, 2026: Grant or award of RGEN shares (Form 4, code A).
- May 7, 2026: Option exercise of RGEN shares (Form 4, code M).
Other insiders filing for Cytek Biosciences, Inc. (CTKB)
- Jiang Wenbin, PRESIDENT AND CEO
- McCombe William D., Chief Financial Officer
- Holder Michael, Director
- Chin Richard, Director
- Yan Ming, CHIEF TECHNOLOGY OFFICER
- Feuchtwang Ilan, Chief Legal Officer, Secretary